agn 190299 has been researched along with tak-875 in 1 studies
| Studies (agn 190299) | Trials (agn 190299) | Recent Studies (post-2010) (agn 190299) | Studies (tak-875) | Trials (tak-875) | Recent Studies (post-2010) (tak-875) |
|---|---|---|---|---|---|
| 6 | 0 | 4 | 121 | 15 | 116 |
| Protein | Taxonomy | agn 190299 (IC50) | tak-875 (IC50) |
|---|---|---|---|
| Sodium/bile acid cotransporter | Homo sapiens (human) | 2 | |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | 2.41 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2.28 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiello, F; Caroleo, MC; Carullo, G; Cione, E; Governa, P; Manetti, F | 1 |
1 review(s) available for agn 190299 and tak-875
| Article | Year |
|---|---|
FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
Topics: Binding Sites; Drug Development; Humans; Hypoglycemic Agents; Ligands; Receptors, G-Protein-Coupled | 2021 |